Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Rogers Corp. (NY: ROG)
46.22 USD  +0.17 (+0.37%)
Official Closing Price  /  Updated: 6:40 PM EDT, May 24, 2013  /  Add to My Watchlist      
View: Quote News Research
All news about Rogers Corp.
 
< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
Rogers Corporation to Present D.A. Davidson & Co. 5th Annual Technology Forum
May 22, 2013
from Business Wire News Releases
Market Chatter-Corporate finance press digest
May 22, 2013
May 22 (Reuters) - The following corporate finance-related stories were reported by media on Wednesday: Read More
category companyNews
from Reuters: Company News
Market Chatter-Corporate finance press digest
May 22, 2013
May 22 (Reuters) - The following corporate finance-related stories were reported by media on Wednesday: Read More
category companyNews
from Reuters: Company News
Roche, Sigma teamed up for failed Life Technologies bid -sources
May 21, 2013
NEW YORK, May 21 (Reuters) - Roche Holding AG teamed up with Sigma-Aldrich Corp to make an unsuccessful bid for Life Technologies Corp earlier this year, people familiar with the matter said. Read More
category companyNews
from Reuters: Company News
Regeneron settles all pending litigation with Roche's Genentech
May 20, 2013
May 20 (Reuters) - Regeneron Pharmaceuticals Inc said it settled all pending litigation with Roche Holding AG's unit Genentech on the company's eye drug, Eylea, and cancer drug, Zaltrap. Read More
category companyNews
from Reuters: Company News
Pfizer halts study of lymphoma drug unlikely to help survival
May 20, 2013
May 20 (Reuters) - Pfizer Inc, which has been on a hot streak with three recent approvals of cancer drugs, stumbled on Monday, saying it was halting a late-stage trial of a drug for aggressive... Read More
category companyNews
from Reuters: Company News
CORRECTED-Data show new Roche leukemia drug may improve on Rituxan
May 16, 2013
(Corrects paragraph 12 to show Biogen has stake in new drug) Read More
category companyNews
from Reuters: Company News
DEALTALK-Novartis' Vasella exit opens door to Roche stake sale
May 16, 2013
* Novartis' one-third stake in Roche built up under Vasella Read More
category companyNews
from Reuters: Company News
RPT-Market Chatter-Corporate finance press digest
May 16, 2013
May 16 (Reuters) - The following corporate finance-related stories were reported by media on Thursday: Read More
category companyNews
from Reuters: Company News
Market Chatter-Corporate finance press digest
May 16, 2013
May 16 (Reuters) - The following corporate finance-related stories were reported by media on Thursday: Read More
category companyNews
from Reuters: Company News
Genentech’s Obinutuzumab (GA101) Significantly Reduced the Risk of Disease Progression or Death in People with One of the Most Common Forms of Blood Cancer
May 15, 2013
from Business Wire News Releases
New cancer tools allow patients to reconsider chemo
May 15, 2013
LOS ANGELES, May 15 (Reuters) - After decades of using one-size-fits-all therapies to combat cancer, doctors are using new tools to help decide when their patients can skip chemotherapy or other harsh... Read More
category companyNews
from Reuters: Company News
Roche immunotherapy shows response over range of cancers
May 15, 2013
May 15 (Reuters) - An experimental Roche Holding AG drug that helps the immune system attack tumors was well tolerated and demonstrated an impressive effect against a variety of cancers, according to... Read More
category companyNews
from Reuters: Company News
Data shows new Roche leukemia drug may improve on Rituxan
May 15, 2013
May 15 (Reuters) - An experimental leukemia treatment that Roche Holding AG hopes will improve upon its best-selling cancer drug Rituxan delayed disease progression twice as long as chemotherapy,... Read More
category companyNews
from Reuters: Company News
Roche banks on new drug data to defend cancer business
May 15, 2013
ZURICH, May 15 (Reuters) - Swiss drugmaker Roche hopes data published this week will show it has a viable follow-on product to help fend off cheaper competition for its best-selling cancer drug, which... Read More
category companyNews
from Reuters: Company News
Genentech to Present Important New Data Reflecting Broad Cancer Pipeline at ASCO
May 15, 2013
from Business Wire News Releases
FDA Approves Tarceva (Erlotinib) Tablets and Cobas EGFR Mutation Test for Specific Type of Lung Cancer
May 14, 2013
from Business Wire News Releases
Rogers Corporation Updates on Cost Improvement Initiatives
May 14, 2013
from Business Wire News Releases
FDA approves Roche diagnostic for gene mutation in lung cancer
May 14, 2013
May 14 (Reuters) - U.S. health regulators on Tuesday approved a test developed by Roche for a specific gene mutation present in about 10 percent of non-small cell lung cancers, and said the company's... Read More
category companyNews
from Reuters: Company News
UPDATE 1-India's top generic drugmakers look to US as patents end
May 08, 2013
MUMBAI, May 8 (Reuters) - India's top drugmakers, among the world's biggest producers of cheap generic medicines, are looking beyond their own shores to generate revenue, seeking to profit from... Read More
category companyNews
from Reuters: Company News
FDA warns shorter name of new Roche cancer drug may cause confusion
May 06, 2013
May 6 (Reuters) - The U.S. health regulator warned on Monday that using a shorter name for Roche's new breast cancer drug Kadcyla may lead to the treatment being confused with an older therapy and... Read More
category companyNews
from Reuters: Company News
Regeneron raises 2013 Eylea sales view, profit beats Street
May 03, 2013
May 3 (Reuters) - Regeneron Pharmaceuticals Inc's first-quarter results beat analysts' estimates for the seventh straight quarter as the sales of its eye drug Eylea continued to gather pace, and the... Read More
category companyNews
from Reuters: Company News
Big drugmakers think small with nanomedicine deals
May 03, 2013
* Early-stage research but scientists see momentum building Read More
category companyNews
from Reuters: Company News
Key trial of Seaside autism drug fails to show benefit
May 01, 2013
* Company says trial offered better idea of who would benefit Read More
category companyNews
from Reuters: Company News
Rogers Corp. (ROG) Misses Q1 EPS by 5c, Q2 Guidance Light
April 30, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8291094 for the full story. Read More
from StreetInsider.com News Articles
Rogers Corporation Reports 2013 First Quarter Results
April 30, 2013
from Business Wire News Releases
FDA Approves ACTEMRA® for Children Living with a Rare Form of Arthritis
April 30, 2013
from Business Wire News Releases
Rogers Corporation to Present at Jefferies 2013 Global Technology, Media and Telecom Conference
April 30, 2013
from Business Wire News Releases
Earnings Scheduled For April 30, 2013
April 30, 2013
Aetna (NYSE: AET ) is expected to report its Q1 earnings at $1.39 per share on revenue of $9.64 billion. Archer Daniels Midland Company (NYSE: ADM ) is estimated to report its Q1 earnings at $0.52 per... Read More
category Earnings , Benzinga , News , and 30 more.
from Latest Articles from Benzinga.com
Trading Radar for 04/30: Pfizer (PFE), Cummins (CMI), McGraw-Hill (MHP), DreamWorks (DWA), Sirius (SIRI) Report
April 29, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8286850 for the full story. Read More
from StreetInsider.com News Articles
< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here